BOSTON and MILAN, Nov. 30, 2023 /PRNewswire/ -- Allotex Inc. and SpA, a leading biologics and device company specializing in vision correction therapies, is pleased to announce that Junson Capital has joined its investor syndicate. This additional capital will help support the expansion of the Company's production facility in preparation for market introduction and US clinical trials..

波士顿和米兰，2023年11月30日/PRNewswire/-Allotex Inc.和SpA，一家专门从事视力矫正疗法的领先生物制剂和设备公司，很高兴地宣布Junson Capital已加入其投资者集团。这项额外资金将有助于支持公司生产设施的扩张，为市场引入和美国临床试验做准备。。

Allotex's innovative approach uses laser-shaped human corneal allografts to reshape the cornea for the treatment of presbyopia, restoring lost reading vision which is caused by the natural aging process. With hundreds of millions of individuals worldwide seeking a safe, effective, and long-lasting alternative to spectacles and contact lenses for reading, the company is poised to make a major impact in the vison care marketplace..

Allotex的创新方法使用激光形状的人体角膜同种异体移植物重塑角膜，用于治疗老花眼，恢复由自然老化过程引起的阅读视力丧失。随着全球数亿人寻求安全，有效和持久的眼镜和隐形眼镜替代品供阅读，该公司准备在vison护理市场产生重大影响。。

Dr. David Muller, Founder and CEO of Allotex, commented on the company's progress, saying, 'This financing will allow Allotex to introduce our groundbreaking technology in Europe and Japan in early 2024 while actively working with the FDA to initiate clinical trials in the United States as soon as possible.

Allotex的创始人兼首席执行官David Muller博士对该公司的进展发表了评论，说：“这项融资将使Allotex于2024年初在欧洲和日本引入我们的开创性技术，同时积极与FDA合作，在美国启动临床试验。尽快。

The additional capital will help support the necessary expansion of our production facilities to increase capacity and ensure a steady supply of products.'.

额外的资金将有助于支持我们生产设施的必要扩张，以提高产能并确保稳定的产品供应。

John White, Allotex Board member representing KCK MedTech commented, 'Our published safety and efficacy results, along with our 4-year follow-up, will boost market acceptance for both patients and refractive surgeons. Surgeons have had confidence in using human corneal allografts for over 70 years and are excited about the potential for our technology to restore reading vision to the millions of people who have age related presbyopia.'.

代表KCK MedTech的Allotex董事会成员John White评论说：“我们公布的安全性和有效性结果以及我们4年的随访结果将提高患者和屈光外科医生的市场接受度。外科医生对使用人类角膜同种异体移植物已有70多年的信心，并且对我们的技术为数百万患有年龄相关性老花眼的人恢复阅读视力的潜力感到兴奋。

Junson Capital has joined the existing investors including KCK MedTech, Panakes, Supernova Invest, and Exor Ventures to complete the Series B financing. Wei Shen, representing Junson Capital, shared their enthusiasm for joining the investor syndicate, stating, 'We are excited to partner with Allotex and contribute to the advancement of their groundbreaking therapies.

Junson Capital已加入现有投资者，包括KCK MedTech，Panakes，Supernova Invest和Exor Ventures，以完成B系列融资。代表Junson资本的Wei Shen分享了加入投资者集团的热情，并表示：“我们很高兴与Allotex合作，并为推进其开创性疗法做出贡献。

The potential to make a significant impact on the global vision-correction market is evident, and we look forward to being a part of this transformative journey.' Junson Capital is a global investment manager with a long dedication to disruptive technology and healthcare leaders and investments across venture capital, private equity, public markets, real estate and alternatives.

对全球视力矫正市场产生重大影响的潜力是显而易见的，我们期待成为这场变革性旅程的一部分Junson Capital是一家全球投资经理，长期致力于颠覆性技术和医疗保健领导者以及风险投资，私募股权，公共市场，房地产和替代品的投资。

Allotex was advised by Cukierman & Co. Life Sciences for this transaction..

Allotex由Cukierman＆Co。Life Sciences建议进行此次交易。。

About Allotex Inc.Allotex Inc. is a pioneering biologics and device company focused on developing innovative therapeutic solutions for vision correction. By utilizing precisely shaped human corneal allografts, Allotex creates a natural, removable inlay, offering patients a safe, permanent vision correction option.

关于Allotex Inc.Allotex Inc.是一家开创性的生物制剂和设备公司，专注于开发用于视力矫正的创新治疗方案。通过使用精确形状的人体角膜同种异体移植物，Allotex创建了一种天然的，可移除的嵌体，为患者提供安全，永久的视力矫正选项。

With a commitment to advancing vision correction, Allotex is dedicated to improving the lives of individuals affected by presbyopia and other refractive disorders of the human eye..

Allotex致力于推进视力矫正，致力于改善受老花眼和其他人眼屈光不正影响的人的生活。。

For more information on Allotex please visit www.allotex.com or contact Travis Henry ([email protected]).

有关Allotex的更多信息，请访问www.Allotex.com或联系Travis Henry（[电子邮件保护]）。

SOURCE Allotex, Inc.

资料来源：Allotex公司。